Biotech Values

[DewDiligence]

VRTX: This table presents the ITT efficacy data from the
Telaprevir ADVANCE trial in a different (and IMO more
helpful) way than in VRTX’s PR. I’m making the simplifying
assumptions that viral breakthroughs during treatment and
late dropouts (i.e. after a patient achieved undetectable VL)
were rare enough to ignore in this “first-order” analysis.)

 
               ‘12+12’  ‘08+16’   SoC 
                 Arm      Arm     48wk 
               (n=362)  (n=364)  (n=369) 
  
 RVR             68%      66%       9% 
  
 Undtctble VL         
 achieved too 
 late for RVR    16%      17%      63% 
                 ===      ===      === 
 Undtctble VL 
 at any time     84%      83%      72% 
  
 Relapse        ( 9%)    (10%)    (28%) 
                =====    =====    ===== 
  
 SVR             75%      73%      44%